Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Campus Bio-Medico University
- Target Recruit Count
- 150
- Registration Number
- NCT01572623
- Locations
- 🇮🇹
Campus Bio Medico University of Rome, Rome, RM, Italy
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 91
- Registration Number
- NCT01561950
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Neptune, New Jersey, United States
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
- Conditions
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 81
- Registration Number
- NCT01543932
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy
A Pharmacodynamic Study With Ticagrelor in African American Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT01523392
- Locations
- 🇺🇸
Research Site, Beaumont, Texas, United States
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT01523366
- Locations
- 🇺🇸
Research Site, Linden, New Jersey, United States
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
- Conditions
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Kaiser Franz Josef Hospital
- Target Recruit Count
- 1008
- Registration Number
- NCT01515345
- Locations
- 🇦🇹
Kaiser Franz Josef Hospital, Vienna, Austria
Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 51
- Registration Number
- NCT01512485
- Locations
- 🇨🇦
Anapharm, Sainte-Foy (Quebec), Canada
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Les Laboratoires des Médicaments Stériles
- Target Recruit Count
- 116
- Registration Number
- NCT01509365
- Locations
- 🇹🇳
cardiology department, hospital Fattouma Bourguiba, Monastir, Tunisia
Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 53
- Registration Number
- NCT01506713
- Locations
- 🇨🇦
Anapharm, Sainte-Foy (Quebec), Canada
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 187
- Registration Number
- NCT01505790
- Locations
- 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.